U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
3220-67883SERIAL NO.
09/822,379

INFORMATION DISCLOSURE STATEMENT

APPLICANT
Low, et al.FILING DATE
March 30, 2001GROSS
UNKNOWNRECEIVED
DEC 21 2001

TECH. CENTER 1600/2900

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
KAC	AA	5,688,488	Nov. 18, 1997	Low et al.	424	1.69	
KAC	AB	5,547,668	Aug. 20, 1996	Kranz et al.	424	181.1	
KAC	AC	5,672,486	Sept. 30, 1997	Souillou	435	69.1	
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
KAC	AL	WO 91/01146	7 Feb. 1991	PCT			
KAC	AM	WO 91/07418	30 May 1991	PCT			
KAC	AN	WO 97/37690	16 Oct. 1997	PCT			
	AO						
	AP						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AR	"Redirection of T Cell-Mediated Cytotoxicity by a Recombinant Single-Chain Fv Molecule," George, et al., <i>Journal of Immunology</i> , 1994, 152: 1802. ✓
	AS	"Immunization with Haptenized, Autologous Tumor Cells Induces Inflammation of Human Melanoma Metastases," Berd et al., <i>Cancer Research</i> , 51, 2731-2734, May 15, 1991. ✓
	AT	"Eliciting Hyperacute Xenograft Response to Treat Human Cancer: $\alpha(1,3)$ Galactosyltransferase Gene Therapy," Link Jr. et al., <i>Anticancer Research</i> , 18: 2301-2308 (1998). ✓
	AU	"Use of Xenogenized (Modified) Tumor Cells For Treatment In Experimental Tumor and In Human Neoplasia," Ben-Efraim et al., <i>Biomed. & Pharmacother.</i> , 2000, 54, 268;73. ✓
	AV	"Immunotoxins - Entry into Cells and Mechanisms of Action," Olsnes et al., <i>Immunology Today</i> , Vol. 10, No. 9, 1989, p. 291. ✓
	AW	"Entry of Protein Toxins in Polarized Epithelial Cells," Melby et al., <i>Cancer Research</i> , 53: 1755-1760, April 15, 1993. ✓
	AX	"Redirecting Circulating Antibodies via Ligand-Hapten Conjugates Eliminates Target Cells In Vivo," Lussow et al., <i>Journal of Immunotherapy</i> , 19(4):257-265 (1996). ✓
	AY	"Targeting of Anti-hapten Antibodies to Activated T Cells via an IL-2-Hapten Conjugate Prolongs Cardiac Graft Survival," Lussow et al., <i>Transplantation</i> , Vol. 62, No. 12, 1703-1708, December 27, 1996. ✓
✓	AZ	"Targeting T Cells Against Brain Tumors With A Bispecific Ligand-Antibody Conjugate," Roy et al., <i>Int J. Cancer</i> , 76: 761-766, (1998). ✓

Examiner


Taron A. Canella

Date Considered

3/5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
3220-67883SERIAL No.
09/822,379

INFORMATION DISCLOSURE STATEMENT

APPLICANT
Low, et al.FILING DATE
March 30, 2001GROUP
UnknownRECEIVED
DEC 21 2001
TECH CENTER 1800/2900

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	BL						
	BM						
	BN						
	BO						
	BP						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	BR	"Intracerebral Bispecific Ligand-Antibody Conjugate Increases Survival of Animals Bearing Endogenously Arising Brain Tumors," Patrick, et al., <i>Int. J. Cancer</i> , 78: 470-479 (1998). ✓
KAL	BS	"Section 23.5: Immunization with Synthetic or Highly Purified Tumor Antigens," Philip Livingston, De Vita, V.T., <i>Biologic Therapy of Cancer</i> , 2d ed. Philadelphia, Lippincott, 1995, pp 680-687.
	BT	
	BU	
	BV	
	BW	
	BX	
	BY	
	BZ	

Examiner


Karen A. Canella

Date Considered

3/5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 3220-67883		SERIAL No. 09/822,379	
				APPLICANT Low et al.			
				FILING DATE March 30, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if
KAC	AA	5,583,202	Dec. 10, 1996	Zanetti, M.			
KAC	AB	5,747,024	May 5, 1998	Grabstein et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
KAC	AR	Guyre, et al., Increased Potency of Fc-receptor-targeted Antigens, <i>Cancer Immunol. Immunotherapy</i> , vol. 45, pp. 146-148, 1997.					
KAC	AS	Lanza, et al., Use of Antigenized Antibodies Containing CD4 Sequences to Generate Antibodies Able to Inhibit Syncytia Formation, <i>FASEB J.</i> , abstract number 2690, page A1400, 1992.					
	AT						
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						
Examiner <i>Karen G. Conella</i>					Date Considered <i>3/5/03</i>		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

BASED ON FORM PTO 1449

COPY OF PAPERS
ORIGINALLY FILED